{/* Overview */}

Unlike small-molecule drugs, which are synthesized chemically and have well-defined molecular structures, biologics are large, complex molecules produced by living cells. This complexity means that the manufacturing process itself defines the product — a principle captured in the regulatory concept that "the process is the product."

Biologics development begins with cell line development — engineering a host cell (typically CHO for monoclonal antibodies, E. coli or yeast for simpler proteins) to express the target molecule. The cell line is then scaled through seed train, fermentation or cell culture, and the product is purified through a sequence of chromatography, viral inactivation and filtration steps.

Analytical characterization of biologics is far more extensive than for small molecules. In addition to identity, potency and purity, biologics require analysis of post-translational modifications (glycosylation, deamidation, oxidation), aggregation, charge variants and immunogenicity-related attributes.

The following sections describe each major modality in our biotechnology portfolio, the underlying science, our bioprocessing capabilities and the future directions of biotechnology research.

Biologics regulatory framework

Viral safety of biotech products from cell lines of human or animal origin. Genetic stability of expression constructs. Stability testing of biotech products. Cell substrate characterization. Comparability of biotech products. Specifications for biotech products. Biological products regulations.

{/* Modalities */}

{[ { icon: Beaker, t: 'Monoclonal antibodies (mAbs)', d: 'Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance or mimic the immune system's attack on cells. Since the first therapeutic mAb approval in 1986, the class has become one of the most commercially and clinically important in medicine, with applications in oncology, immunology, infectious disease and ophthalmology. Modern mAbs are typically humanized or fully human, produced in mammalian cell culture (predominantly CHO cells), and purified through Protein A chromatography followed by polishing steps. Characterization includes glycan profiling (HILIC), charge variants (icIEF, IEX), aggregation (SEC, MFI), and potency (cell-based bioassay).', }, { icon: FlaskConical, t: 'Recombinant proteins', d: 'Recombinant proteins are produced by expressing a gene of interest in a host cell — bacterial (E. coli), yeast (P. pastoris, S. cerevisiae), insect or mammalian. Recombinant technology underlies insulin, erythropoietin, growth hormone, follicle-stimulating hormone, enzyme replacement therapies (e.g., for lysosomal storage disorders) and many other biologics. Host selection balances expression level, post-translational modification requirements and regulatory familiarity. Downstream purification typically includes cell lysis (for intracellular expression), capture chromatography, polishing steps and — for proteins from mammalian cell culture — viral clearance.', }, { icon: Syringe, t: 'Cell therapy', d: 'Cell therapy involves the administration of living cells to treat disease. The best-established example is hematopoietic stem cell transplantation, practiced for decades. Newer modalities include CAR-T cell therapy — in which a patient's T cells are genetically engineered to express a chimeric antigen receptor targeting tumor cells — and mesenchymal stromal cell therapy. Manufacturing is inherently complex: cells must be isolated, modified, expanded and characterized within tight time constraints, often in a patient-specific autologous workflow. Quality release includes viability, identity, sterility, endotoxin and potency assays.', }, { icon: Dna, t: 'Gene therapy overview', d: 'Gene therapy aims to treat disease by modifying the genetic content of cells. Current approaches include in vivo gene therapy (direct administration of a vector — typically adeno-associated virus, AAV — carrying a therapeutic gene) and ex vivo gene therapy (genetic modification of patient cells outside the body, followed by re-infusion). Gene editing with CRISPR-Cas has expanded the field to include not only gene addition but gene correction. Manufacturing of viral vectors for gene therapy is a specialized activity, with scale-up of suspension cell culture and chromatography-based purification.', }, ].map((m, i) => { const Icon = m.icon return (

{`0${i + 1}`}

{m.t}

{m.d}

) })}

{/* Bioprocessing */}

{[ { icon: Microscope, t: 'Cell line development', d: 'Host cell selection, transfection, single-cell cloning, selection and cell banking (MSB, WCB). ICH Q5D cell substrate characterization includes identity, sterility, mycoplasma, viral testing and genetic stability.' }, { icon: Atom, t: 'Upstream processing', d: 'Seed train expansion, bioreactor operation (fed-batch, perfusion), process control (pH, DO, temperature, feeding). Single-use and stainless-steel bioreactors from bench to commercial scale.' }, { icon: Beaker, t: 'Downstream processing', d: 'Harvest clarification, capture chromatography (Protein A for mAbs), viral inactivation (low pH hold), polishing chromatography (IEX, HIC), viral filtration (parvovirus-retentive), ultrafiltration/diafiltration (UF/DF).' }, { icon: Activity, t: 'Formulation & fill', d: 'Buffer exchange, concentration, excipient addition, sterile filtration and aseptic filling. Lyophilization for unstable molecules. Container closure options include vials, pre-filled syringes and cartridges.' }, { icon: FlaskConical, t: 'Analytical release', d: 'Identity (peptide mapping), purity (SEC, CE-SDS), charge (icIEF), potency (cell-based bioassay), glycan profiling (HILIC), aggregation (MFI, HIAC), endotoxin, bioburden, mycoplasma.' }, { icon: Microscope, t: 'Comparability', d: 'ICH Q5E comparability studies for process changes — analytical, biological and — where necessary — clinical comparability. Demonstrates that pre- and post-change products are comparable in quality, safety and efficacy.' }, ].map((b, i) => { const Icon = b.icon return (

{b.t}

{b.d}

) })}

{/* Fermentation & cell culture */}

Microbial fermentation

E. coli, yeast and beyond

Microbial fermentation is fast, scalable and cost-effective for proteins that do not require complex post-translational modifications. E. coli is the workhorse for insulin, growth hormone and many antibody fragments. Yeast (P. pastoris, S. cerevisiae) supports limited glycosylation and is used for vaccines and some enzymes.

Process considerations include induction strategy, oxygen transfer, by-product formation, inclusion body refolding (E. coli), and scale-down/scale-up using kLa and tip-speed matched bioreactors.

Mammalian cell culture

CHO and human cell lines

Mammalian cell culture is the platform of choice for monoclonal antibodies and complex proteins requiring human-compatible glycosylation. CHO cells dominate, with human (HEK293) and mouse (NS0, Sp2/0) lines used in specific contexts.

Process considerations include chemically defined media, fed-batch and perfusion modes, glucose/lactate metabolism, osmolality control, and glycan engineering. Process intensification and perfusion are increasingly used to improve volumetric productivity.

{/* Future biotech */}

{[ { t: 'mRNA therapeutics', d: 'Beyond vaccines, mRNA is being developed for cancer immunotherapy, protein replacement and in vivo gene editing delivery.' }, { t: 'Gene editing', d: 'CRISPR-Cas9, base editors and prime editors enabling precise genome modification for monogenic disease and beyond.' }, { t: 'Regenerative medicine', d: 'iPSC-derived cell therapies, tissue engineering and organoid-based approaches for degenerative disease.' }, { t: 'Multispecific biologics', d: 'Bispecific and multispecific antibodies, ADCs and protein fusions that engage multiple biological pathways simultaneously.' }, { t: 'Conjugate therapies', d: 'Antibody–drug, antibody–oligonucleotide and antibody–radionuclide conjugates for targeted payload delivery.' }, { t: 'AI-designed proteins', d: 'De novo protein design using machine learning opens entirely new therapeutic modalities not found in nature.' }, { t: 'Microbiome therapies', d: 'Live biotherapeutic products and microbiome-derived metabolites for gastrointestinal and systemic indications.' }, { t: 'Synthetic biology', d: 'Engineered cell circuits, smart therapies that respond to disease signals, and programmable biomanufacturing.' }, ].map((f, i) => ( 0{i + 1}

{f.t}

{f.d}

))}

navigate('research')}> Research & development navigate('innovation')}> Innovation roadmap navigate('cdmo')}> CDMO biologics services